



## Dyne Therapeutics to Present at Investor Conferences in November

November 2, 2022

WALTHAM, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- [Dyne Therapeutics, Inc.](https://www.dyne-tx.com) (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to present at the following investor conferences in November:

- **Credit Suisse 31<sup>st</sup> Annual Healthcare Conference**, presentation on November 9, 2022 at 11:00 a.m. PT (2:00 p.m. ET) in Rancho Palos Verdes, CA
- **Jefferies London Healthcare Conference**, fireside chat on November 16, 2022 at 12:20 p.m. GMT (7:20 a.m. ET) in London
- **Stifel 2022 Healthcare Conference**, fireside chat on November 16, 2022 at 11:30 a.m. ET in New York
- **Piper Sandler 34<sup>th</sup> Annual Healthcare Conference**, fireside chat on November 29, 2022 at 11:00 a.m. ET in New York

A live webcast of each presentation will be available in the Investors & Media section of Dyne's website at <https://investors.dyne-tx.com/news-and-events/events-and-presentations> and a replay will be accessible for 90 days.

### About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to muscle tissue seen with other approaches. Dyne has a broad portfolio of programs for serious muscle diseases, including candidates for myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). For more information, please visit <https://www.dyne-tx.com/>, and follow us on [Twitter](#), [LinkedIn](#) and [Facebook](#).

### Contact:

Dyne Therapeutics  
Amy Reilly  
[areilly@dyne-tx.com](mailto:areilly@dyne-tx.com)  
857-341-1203